Yadav Satya Prakash, Sachdeva Anupam, Bhat Sunil, Katewa Satyendra
Pediatric Hematology Oncology & BMT Unit, Department of Pediatrics, Sir Ganga Ram Hospital, New Delhi, India.
Pediatr Hematol Oncol. 2010 Feb;27(1):24-30. doi: 10.3109/08880010903376988.
Post hematopoietic stem cell transplantation (HSCT) gastrointestinal (GI) bleeding is a dreaded complication. There are only five other reports (one randomised trial and four case reports) of use of rFVIIa for massive lower GI bleeding post-allogeneic HSCT. In only one publication, two adult patients showed complete response. Eroglu has reported a response rate of 50% to octreotide in gastrointestinal bleeding in patients without portal hypertension. We present a 10 month-old female child, who had three episodes of life threatening lower GI bleeding post unrelated Umbilical Stem Cell Transplant (UCBT) controlled successfully each time by use of rFVIIa and octreotide infusion and review of literature. To our knowledge this is the first and youngest case reported, in which both rFVIIa and octreotide have been used successfully to control life threatening lower GI bleeding post UCBT.
造血干细胞移植（HSCT）后胃肠道（GI）出血是一种可怕的并发症。关于重组活化凝血因子VII（rFVIIa）用于异基因造血干细胞移植后大量下消化道出血的情况，仅有另外五篇报道（一篇随机试验和四篇病例报告）。只有一篇出版物中，两名成年患者显示出完全缓解。埃罗格鲁报道了奥曲肽对无门静脉高压患者胃肠道出血的有效率为50%。我们报告一名10个月大的女童，在接受非亲缘脐血干细胞移植（UCBT）后发生了三次危及生命的下消化道出血，每次均通过使用rFVIIa和奥曲肽输注成功控制，并对文献进行了回顾。据我们所知，这是首例且年龄最小的病例报道，其中rFVIIa和奥曲肽均成功用于控制UCBT后危及生命的下消化道出血。
